Sanofi's Lantus insulin reduced blood-sugar levels to a greater degree than Merck's Januvia in people with Type 2 diabetes in a clinical trial.
WSJ.com: US Business, Wall Street Journal: Business
Sun, 06/10/2012 - 4:34pm
Sanofi's Lantus insulin reduced blood-sugar levels to a greater degree than Merck's Januvia in people with Type 2 diabetes in a clinical trial.